The maternal serum glycosylated fibronectin (GlyFn) was reported to be elevated in all three trimesters of preeclampsia patients; the test was further recommended as a point‐of‐care biomarker to quickly determine risk for preeclampsia and for poor maternal and fetal outcomes among preeclamptic patients.13 This evidence concerns the gene FN1 and preeclampsia.